Live tape
Top 8, mentions 7d7,230GOOGL1,604 mentions▲ +0.03NKE1,550 mentions▲ +0.03META1,034 mentions▲ +0.05NVDA899 mentions▲ +0.10TSLA607 mentions▲ +0.05MSFT520 mentions▲ +0.04RBA515 mentions▲ +0.05AMZN501 mentions▲ +0.06

Equity · Healthcare

ARWR

NASDAQ

Arrowhead Pharmaceuticals, Inc.

$64.77 −0.35% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 1, 2026
Price · Chart
Our own end-of-day closes 63 sessions
$90 $60 6 Jul 1 Oct

The line runs $86.55 on 6 July through $64.77 on 1 October, on a scale from $60 to $90. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ARWR over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 63 sessions over that window: $86.55 on 6 July 2026 through $64.77 on 1 October 2026.

Market cap $9.1B
52-week range $31.64 – $89.61
Avg volume 103.3K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Oct 1, 2026

ARWR insider trades

SEC Form 4 · last 90 days · newest reported trade 18 Aug 2026
Open-market buys 0
Open-market sells 2
Net sold $1.19M
Non-trade filings 0
Date Insider Type Shares Value
18 Aug 2026 OLUKOTUN ADEOYE Y Director Sell 2,000 $174K
18 Aug 2026 PERRY MICHAEL S Director Sell 11,600 $1.01M

ARWR reported financials

SEC EDGAR XBRL

ARWR reported revenue of $829.4M for the fiscal year ended 30 Sep 2025. Net income over the same period was −$1.6M.

Figure Reported Period
Revenue $829.4M 30 Sep 2025 fiscal year
Net income −$1.6M 30 Sep 2025 fiscal year
Diluted EPS −$0.01 30 Sep 2025 fiscal year
Total assets $2.1B 30 Jun 2026 at period end
Total equity $465.5M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ARWR earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q3 2026 $-1.36 —
31 Mar 2026 Q2 2026 $-0.93 —
31 Dec 2025 Q1 2026 $0.22 —
30 Sep 2025 FY 2025 $-0.01 —
30 Jun 2025 Q3 2025 $-1.26 —
31 Mar 2025 Q2 2025 $2.75 —
31 Dec 2024 Q1 2025 $-1.39 —
30 Sep 2024 FY 2024 $-5.00 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ARWR institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a ARWR position for the quarter ended 30 Jun 2026 — a combined $467.1M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 1,992,783 $162.4M
Fisher Asset Management Held (±25%) −14.0% shares 957,691 $78.1M
Two Sigma Investments Added +1,521.8% shares 580,609 $47.3M
Balyasny Asset Management Added +128.1% shares 470,754 $38.4M
Renaissance Technologies Trimmed −54.8% shares 468,921 $38.2M
D. E. Shaw & Co. Trimmed −63.5% shares 431,560 $35.2M
Millennium Management New position 329,337 $26.8M
Marshall Wace Added +69.9% shares 305,031 $24.9M
AQR Capital Management Held (±25%) +18.9% shares 198,842 $15.8M
Bridgewater Associates Exited

Source: SEC EDGAR 13F filings

ARWR fails-to-deliver

SEC CNS data

On 19 Aug 2026, 16,510 shares of ARWR failed to deliver (about $1.5M).

Settlement date Shares failed Notional % of shares out
19 Aug 2026 16,510 $1.5M 0.012%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in ARWR

STOCK Act disclosures

The most recent congressional trade disclosed in ARWR is a sale by Daniel S. Goldman (house, NY), dated 31 Jan 2023.

Date Member Type Amount
31 Jan 2023 filed 24 Feb 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures